178 related articles for article (PubMed ID: 38363382)
1. The novel miR-873-5p-YWHAE-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy.
Li Z; Liu J; Wang P; Zhang B; He G; Yang L
Funct Integr Genomics; 2024 Feb; 24(2):33. PubMed ID: 38363382
[TBL] [Abstract][Full Text] [Related]
2. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta.
Shi L; Kan J; Zhuo L; Wang S; Chen S; Zhang B; Ke B
FEBS J; 2023 Feb; 290(4):1134-1150. PubMed ID: 36180981
[TBL] [Abstract][Full Text] [Related]
4. miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.
Chen FF; Sun N; Wang Y; Xi HY; Yang Y; Yu BZ; Li XJ
J Cell Physiol; 2020 Oct; 235(10):7273-7282. PubMed ID: 32039486
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
6. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
10. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
11. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
Sun B; Hu N; Cong D; Chen K; Li J
Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
[TBL] [Abstract][Full Text] [Related]
13. Circ_0091537 promotes gefitinib chemoresistance in non-small cell lung cancer by mediating the miR-520h/YAP1 network.
Qu R; Ma J
Anticancer Drugs; 2023 Nov; 34(10):1151-1161. PubMed ID: 36727737
[TBL] [Abstract][Full Text] [Related]
14. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
Niu R; Li D; Chen J; Zhao W
Cell Cycle; 2022 Jan; 21(1):86-100. PubMed ID: 34919024
[TBL] [Abstract][Full Text] [Related]
15. Circ_SETD3 regulates gefitinib sensitivity and tumor progression by miR-873-5p-dependent regulation of APPBP2 in non-small cell lung cancer.
Sheng J; Liu L; Dong T; Wu X
J Chemother; 2022 Oct; 34(6):401-413. PubMed ID: 34861803
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
Han J; Hu J; Sun F; Bian H; Tang B; Fang X
Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
[TBL] [Abstract][Full Text] [Related]
17. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1.
Zhang T; Wang N
Oncol Res; 2018 Sep; 26(8):1191-1200. PubMed ID: 29386087
[TBL] [Abstract][Full Text] [Related]
18. MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.
Chen Y; Wu L; Bao M
Mol Biotechnol; 2023 May; 65(5):794-806. PubMed ID: 36219369
[TBL] [Abstract][Full Text] [Related]
19. The circ-PITX1 promotes non-small cell lung cancer development via the miR-30e-5p/ITGA6 axis.
Li W; Yang P; Zhong C; Shen X; Shi X; Li X
Cell Cycle; 2022 Feb; 21(3):304-321. PubMed ID: 35007184
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA PRNCR1 modulates non-small cell lung cancer cell proliferation, apoptosis, migration, invasion, and EMT through PRNCR1/miR-126-5p/MTDH axis.
Guo R; Hu T; Liu Y; He Y; Cao Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 31912882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
